CN丨 EN

Welcome to Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.！

Home丨 Contact Us

Search
Register

Copyright:  Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.！   京ICP备19006400号-1​     Powered by 300.cn

About Us
Company Overview
Advisors
Qualifications
Memorabilia
Technology
Technology Platform
Products
Intellectual Property
Clinical Programs
Cooperative Partners
Clinical Indications
Clinical Cases
Science
Stem Cells
Stem Cell-Derived Exosomes
Stem Cell Factors
News Center
Company News
Press Release
Contact Us
Contact Us
Videos
Download Center
Online Message

美科

Jiuzhitang丨 Mudanjiang Youbo Pharmaceutical 丨 Beijing Tiantan Hospital丨 No.1 Hospital-Harbin Medical Sciences University丨 Stemedica丨

Links：

Stemedica mesenchymal stem cells were approved and listed by Ministry of Health of Kazakhstan as a treatment of acute myocardial infarction.

Source:
Release time：
2018/09/12 16:32
Page view

用Stemedica干细胞治疗急性心梗获得哈萨克斯坦卫生部批准上市。

Previous article:
Press Conference of Jiuzhitang Qihang Fund’s Investment in Stemedica Cell Technologies, Inc. & Global Stem Cell Industry Development Summit was successfully held in Beijing.
Jiuzhitang Maker signed cooperation contracts respectively with Novastem (a Mexican corporation) and ALTACO XXI (a Kazakhstan corporation) on co-construction of internationalized stem cells research and development platforms.
Next article: